%0 Clinical Trial, Phase II
%T Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
%A Laquer V
%A Parra V
%A Lacour JP
%A Takahashi H
%A Knorr J
%A Okragly AJ
%A James DE
%A Sims JT
%A Chang CY
%A Chao J
%A Klekotka P
%J Br J Dermatol
%V 187
%N 4
%D 10 2022
%M 35481678
%F 11.113
%R 10.1111/bjd.21631
%X